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Figure. Kaplan-Meier Survival Estimate, n¼36.
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more respiratory tract infections treated with antimicro-
bials, most often due to Pseudomonas spp (n¼7), Aspergillus
spp (n¼5), inﬂuenza (n¼4) and parainﬂuenza (n¼4). Overall
survival of the cohort was 72% with a median follow-up of
16 months (range 3-32). The primary causes of death in 8
subjects were complications of cGVHD (n¼5) including BOS,
relapse (n¼2), and infection (n¼1). These data suggest the
following: there may be exposures that are risk factors for
BOS after HCT, lung function loss is moderately severe at
diagnosis whether prompted by symptoms or PFT, and pa-
tients with BOS have high morbidity and mortality directly
associated with cGVHD of the lung, even when treated early
after diagnosis.
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: The transition from transplant center to local
oncologist and from local housing to home demands both
practical and emotional consideration. Transplant Nurse
Coordinators (TNCs) and Clinical Social Workers (CSWs) are
in a unique position to help patients and caregivers in this
transition. With proper education, patients and caregivers
are better equipped to handle discharge. The use of a group
modality allows patients and caregivers the opportunity to
learn from one another.
Methods, Intervention, & Analysis: TNCs and CSWs met to
develop a program to address the transition from transplant
center care to home. Content input was secured from other
nurses, social workers, and physicians in the outpatient BMT
program based on the perceived need for support of pa-
tients during this critical time. A group modality was chosen
in an effort to utilize peer learning and support.
All patients who underwent an allogeneic transplant
were scheduled to attend the program prior to dischargefrom the transplant center, between day +60 and day +90. A
slide presentation was developed and focused on the
following areas: communication between the transplant
center and the local oncologist, necessary precautions, rec-
ommended follow-up care, practical aspects of insurance,
employment, ﬁnances and emotional concerns including
managing anxiety, depression, and adjusting to the “new
normal.” Group discussions and reﬂection of the transplant
experience and future goals were facilitated by the TNCs and
CSWs. Evaluations were obtained from each participant at
their next clinic visit.
Findings & Interpretations: Overall, patients and caregivers
rated the group experience and information provided as
informative and thought provoking. 97% of participants
“strongly agreed/agreed” that the topics presented assisted
them in planning their discharge from both a practical and
emotional perspective. 93% reported feeling comfortable
participating in the group discussions.
Discussion & Implications: The beneﬁt of an interdisci-
plinary model between TNCs and CSWs provides a
broad perspective relative to BMT patients transitioning
home. The use of discussion, as well as slide presentation,
helps to individualize education for participants,
creates an environment for discussing questions and
concerns, and allows patients and caregivers to share
experiences and receive support. Another class relative to
the period of post-transplant days +30 to +45 is under
consideration.217
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Background: Respiratory syncytial virus (RSV) infection is
a serious complication post allogeneic stem cell trans-
plant. Aerosolized ribavirin is a commonly used therapy;
however, oral ribavirin is an alternative with many ad-
vantages. There is paucity in literature regarding treat-
ment outcomes using the oral form. Recently, the
immunodeﬁciency scoring index (ISI) was derived from
the largest reported RSV cohort to date using aerosolized
ribavirin.
Objectives: We sought to investigate whether the ISI is
predictive of mortality and lower respiratory tract infection
(LRTI) progression in an independent cohort of RSV infected
allogeneic transplant recipients treated with oral ribavirin
therapy.
Methods: Consecutive patients diagnosed with RSV infec-
tion seen at Mayo Clinic Rochester from 2008e2014 were
identiﬁed. Clinical and pathologic data were retrospectively
abstracted after obtaining IRB approval. The ISI (Blood 2014)
score was calculated for each patient. Survival estimates
were done using the Kaplan-Meier method and log rank test
was used to compare the risk groups.
Results: A total of 53 patients tested positive for RSV infec-
tion. Twenty-eight were female (53%) and the median age at
RSV infection was 55 years (range 15-71). Stem cell source
was peripheral blood in 44 (83%), 7 bonemarrow (13%) and 2
were double cord (4%). Indication for transplant was myeloid
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(30%) and plasma cell dyscrasia in 3 (6%). Sixteen (30%) had
myeloablative conditioning. Median time from onset of
symptoms to diagnosis was 2 days (0-15) and median time
from transplant to diagnosis was 11 months (0-48). Twenty-
eight patients (53%) had URTI symptoms at presentation, 11
(21%) had LRTI and 14 (26%) had progression from URTI to
LRTI. Stratifying per the ISI criteria, 16 patients (30%) were
low risk, 31 (59%) were moderate and 6 (11%) were high risk.
Median survival post RSV diagnosis was 17 months (0-78).
Forty-six patients received oral ribavirin, 4 received aero-
solized ribavirin and 3 were not treated. Five patients (3 high
and 2 moderate risk) had RSV associated mortality with a
median time to death of 8 days (7-18) due to respiratory
failure and/or acute respiratory distress syndrome. Case fa-
tality among high, moderate and low risk patients were 50%,
6% and 0%, respectively. Overall survival was statistically
signiﬁcant among the risk groups (P 0.0112). Predicting LRTI
at diagnosis and risk of URTI to LRTI progression was how-
ever not signiﬁcant (P 0.1375 and 0.4505, respectively).
Conclusion: Use of oral ribavirin in low and moderate risk
patients was associated with an excellent outcome. The ISI
predicted survival but not risk of LRTI post RSV infection in
an independent cohort of allogeneic stem cell transplant
recipients treated with oral ribavirin. Elevated case fatality in
high risk cases highlights the need for better therapies in this
group of patients.
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There is a critical need to increase awareness of late compli-
cations and recommended preventive care among patients
and providers and to improve patient-provider and provider-
provider communication about long-term care post-HCT.
During transition from transplant center back to community,
care often becomes fragmented and insufﬁcient to address
survivors’ complexmedical needs.Weconducted focusgroups
to characterize patient-centered elements that will increase
the acceptability of an individualized treatment summary and
survivorship care plan instrument (SCP). A SCPwas developed
that uses disease and transplant related data routinely sub-
mitted by centers to the CIBMTR. The treatment summary
incorporates these data and identiﬁes important treatment
exposures (age, gender, HCT type, GVHD, TBI and steroid). The
care plan uses these risk factors and long-term followup
guidelines (Majhail et al, BBMT/BMT 2012) to provide patient-
speciﬁc recommendations for preventive care. Phone focus
groups (N¼12) were conducted for: 1) adult allogeneic re-
cipients >1 year post-HCT and their caregivers (3 groups,
N¼22); 2) hematology-oncology and primary care practice
physicians/mid-level providers (3 groups, N¼24); 3) HCT cli-
nicians (2 groups, N¼14); and 4) HCT nurses/social workers (4p care and SCP identiﬁed in focus groups.
